Back to Search
ELIZABETH TREHU, M.D.
M.D.
Medical Oncology Physician
NPI: 1598901068Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
72097(MA)
Research & Publications (7)
Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
PMID 18467736·J Clin Oncol·2008
8-other
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
PMID 18316568·Clin Cancer Res·2008
3-trial
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
PMID 16606971·J Clin Oncol·2006
3-trial
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
PMID 15626743·Blood·2005
3-trial
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
PMID 15613699·J Clin Oncol·2005
3-trial
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PMID 15613697·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 55 CAMBRIDGE PKWY
CAMBRIDGE, MA 02142 - Phone
- (617) 761-8691
Quick Facts
- NPI
- 1598901068
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 7
Are you this provider?
Claim Your Profile